Comparison 22. Adverse events ‐ febuxostat 80 mg/day versus allopurinol 200 or 300 mg/day.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 TOTAL	3	2556	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.89, 0.99]
1.1 24‐28 weeks	2	2047	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.87, 1.00]
1.2 52 weeks	1	509	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.87, 1.02]
2 Serious	3	2556	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.55, 1.42]
2.1 24‐28 weeks	2	2047	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.65, 1.65]
2.2 52 weeks	1	509	Risk Ratio (M‐H, Random, 95% CI)	0.57 [0.28, 1.18]
3 Liver function test abnormalities	3	2556	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.76, 1.39]
3.1 24‐28 weeks	2	2047	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.77, 1.47]
3.2 52 weeks	1	509	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.34, 1.92]
4 Skin reaction	3	2556	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.56, 1.09]
4.1 24‐28 weeks	2	2047	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.58, 1.14]
4.2 52 weeks	1	509	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.03, 2.20]
5 Cardiovascular events (chest pain, coronary artery disease, myocardial infarction, atrial fibrillation)	3	2556	Risk Difference (M‐H, Fixed, 95% CI)	‐0.00 [‐0.02, 0.01]
5.1 24‐28 weeks	2	2047	Risk Difference (M‐H, Fixed, 95% CI)	‐0.00 [‐0.02, 0.01]
5.2 52 weeks	1	509	Risk Difference (M‐H, Fixed, 95% CI)	0.0 [‐0.01, 0.01]
6 Hypertension	3	2556	Risk Ratio (M‐H, Fixed, 95% CI)	4.35 [1.25, 15.09]
6.1 24‐28 weeks	2	2047	Risk Ratio (M‐H, Fixed, 95% CI)	4.35 [1.25, 15.09]
6.2 52 weeks	1	509	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Diarrhea	3	2556	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.64, 1.18]
7.1 24‐28 weeks	2	2047	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.62, 1.18]
7.2 52 weeks	1	509	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.38, 2.59]